Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
On May 22, 2020, the Food and Drug Administration approved brigatinib (ALUNBRIG®, ARIAD Pharmaceuticals Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. Read more. 
Did you know that ASCO has been providing virtual consulting support for years now? Has the pandemic exposed areas within your practice operationally or clinically that needs an independent perspective for improvement? Have a conversation with us to see how we have been supporting practices virtually and how we can support your practice as well. Contact us at clinicalaffairs@asco.org.
On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA®, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. Read more. 
JCO Oncology Practice (JCO OP) published a brand-new infographic that outlines implementation of the American Society of Clinical Oncology’s updated Patient-Centered Oncology Payment (PCOP) model, an oncology-specific alternative payment model designed to transform cancer care delivery and reimbursement while ensuring that people with cancer have access to high-quality care.
Share ASCO Answers with your patients during their visits. Direct, easy to understand, and in three convenient formats, ASCO Answers materials introduce patients and their caregivers to types of cancer and cancer-related topics, including treatments and side effects. Members save 20%. Free domestic shipping. Browse ASCO Answers.
On May 15, 2020, the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA®, Clovis Oncology, Inc.) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Read more.
On January 1, 2021 significant changes will be coming to the office and outpatient Evaluation and Management services. Begin the process of preparing your practice with these three steps:
ASCO released the ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemic, which provides detailed guidance to oncology practices on the immediate and short-term steps that could be taken to help protect the safety of patients and healthcare staff before resuming more routine care operations during the COVID-19 public health crisis.